GlobeNewswire

Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update
04/11/2026
VAX-31 Adult Indication: Announced Positive Topline Data from OPUS-1 Pivotal Phase 3 Trial; VAX-31 Met All Prespecified Primary Endpoints, Was Well Tolerated and Demonstrated a Safety Profile Similar to PCV20 and PCV21 [...]
PROCEPT BioRobotics Reports Third Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance
04/11/2026
SAN JOSE, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics ® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions [...]
Adaptive Biotechnologies Reports Third Quarter 2026 Financial Results
04/11/2026
SEATTLE, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive [...]
Mineralys Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
04/11/2026
– Commercialization plans for lorundrostat are on track ahead of PDUFA target date of December 22, 2026 – – New analyses from the pivotal Launch-HTN trial showed 46% of participants with uncontrolled or resistant [...]
Sight Sciences Reports Third Quarter 2026 Financial Results and Raises Full-Year 2026 Revenue Guidance
04/11/2026
MENLO PARK, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, [...]
PacBio Announces Third Quarter 2026 Financial Results
04/11/2026
MENLO PARK, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2026. Recent Business Highlights Delivered total revenue of $40.6 million [...]
Myriad Genetics Reports Third Quarter 2026 Financial Results; Raises Mid-Point of Full-Year 2026 Revenue Guidance Following Solid Execution Definitive Agreement to Sell Prenatal Health Business to Support Strategic Growth Initiatives
04/11/2026
Highl ights Third quarter 2026 revenue was $202.7 million, representing a 6% sequential increase and a 1% decrease year-over-year. Higher Cancer Care Continuum (CCC) product mix and continued progress on payer [...]
LeMaitre Q3 2026 Financial Results
04/11/2026
BURLINGTON, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q3 2026 results, announced a quarterly dividend of $0. [...]
Tenaya Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
04/11/2026
Received Regenerative Medicine Advanced Therapy (RMAT) Designation from U.S. FDA for TN-401 Gene Therapy for PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy TN-201 and TN-401 Program Updates on Upcoming [...]
Agomab to Participate in Upcoming Investor Conferences
04/11/2026
Antwerp, Belgium, November 4, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced that members of the management team will [...]
Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress
04/11/2026
Received U.S. FDA approval and launched RASONQUE ® (daraxonrasib) for adult patients with metastatic pancreatic cancer who have received at least one prior systemic therapy or who are not candidates for multiagent [...]
Baird Medical Issues Statement Regarding Recent Share Price Volatility
04/11/2026
NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Limited (NASDAQ: BDMD) (“Baird Medical” or the “Company”), a healthcare innovator dedicated to microwave ablation (MWA) technology, has [...]
Eton Pharmaceuticals to Present at 2026 Jefferies Global Healthcare Conference in London
04/11/2026
DEER PARK, Ill., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare [...]
Edesa Biotech to Present at Guggenheim Healthcare Innovation Conference
04/11/2026
TORONTO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today [...]
STERIS Announces Financial Results for Fiscal 2027 Second Quarter
04/11/2026
Fiscal 2027 second quarter revenue increased 9%; constant currency organic revenue growth was 8% Fiscal 2027 second quarter as reported diluted EPS increased to $2.19; adjusted EPS per diluted share increased to $2.94 [...]
Monthly information on share capital and company voting rights
04/11/2026
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 Date Total number of shares in the [...]
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
04/11/2026
(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) PARIS, 04 nov. 2026 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 Date Nombre total d’actions composant le [...]
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04/11/2026
MALVERN, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health and provider of NeuroStar ® TMS technology and direct patient care through the Greenbrook [...]
FocalTherics™ to Participate in Upcoming Investor Conferences
04/11/2026
FocalTherics ™ to Participate in Upcoming Investor Conferences AUSTIN, Texas, Nov. 04, 2026 (GLOBE NEWSWIRE) -- FocalTherics (Nasdaq: FOCL) (the “Company”), a global leader in robotic focal therapy, today announced that [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum